Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists.

Duman RS, Li N.

Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2475-84. doi: 10.1098/rstb.2011.0357. Review.

2.

Signaling pathways underlying the rapid antidepressant actions of ketamine.

Duman RS, Li N, Liu RJ, Duric V, Aghajanian G.

Neuropharmacology. 2012 Jan;62(1):35-41. doi: 10.1016/j.neuropharm.2011.08.044. Epub 2011 Sep 2. Review.

3.
4.

Spine synapse remodeling in the pathophysiology and treatment of depression.

Duman CH, Duman RS.

Neurosci Lett. 2015 Aug 5;601:20-9. doi: 10.1016/j.neulet.2015.01.022. Epub 2015 Jan 9. Review.

5.

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG.

J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. Review.

PMID:
24388038
6.

NMDA antagonist treatment of depression.

Williams NR, Schatzberg AF.

Curr Opin Neurobiol. 2016 Feb;36:112-7. doi: 10.1016/j.conb.2015.11.001. Epub 2015 Dec 11. Review.

PMID:
26687375
7.

Synaptic mechanisms underlying rapid antidepressant action of ketamine.

Kavalali ET, Monteggia LM.

Am J Psychiatry. 2012 Nov;169(11):1150-6. Review.

PMID:
23534055
8.

Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections.

Duman RS.

Depress Anxiety. 2014 Apr;31(4):291-6. doi: 10.1002/da.22227. Epub 2014 Mar 10. Review.

9.

Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.

Dwyer JM, Duman RS.

Biol Psychiatry. 2013 Jun 15;73(12):1189-98. doi: 10.1016/j.biopsych.2012.11.011. Epub 2013 Jan 4. Review.

10.

Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.

Wohleb ES, Gerhard D, Thomas A, Duman RS.

Curr Neuropharmacol. 2017;15(1):11-20. Review.

11.

The role of mTOR in depression and antidepressant responses.

Abelaira HM, RĂ©us GZ, Neotti MV, Quevedo J.

Life Sci. 2014 Apr 17;101(1-2):10-4. doi: 10.1016/j.lfs.2014.02.014. Epub 2014 Feb 25. Review.

PMID:
24582593
12.

Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.

Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM.

Mol Psychiatry. 2013 Dec;18(12):1236-41. doi: 10.1038/mp.2013.87. Epub 2013 Jul 23. Review.

13.

The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.

Masi G, Brovedani P.

CNS Drugs. 2011 Nov 1;25(11):913-31. doi: 10.2165/11595900-000000000-00000. Review.

PMID:
22054117
14.

What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.

Strasburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, Pough KA, Prince TA, Ramsey NS, Savsani KH, Scandlen L, Cavaretta MJ, Raffa RB.

J Clin Pharm Ther. 2017 Apr;42(2):147-154. doi: 10.1111/jcpt.12497. Epub 2017 Jan 22. Review.

PMID:
28111761
15.

Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Licznerski P, Duman RS.

Neuroscience. 2013 Oct 22;251:33-50. doi: 10.1016/j.neuroscience.2012.09.057. Epub 2012 Oct 2. Review.

16.

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS.

Annu Rev Pharmacol Toxicol. 2014;54:119-39. doi: 10.1146/annurev-pharmtox-011613-135950. Review.

17.

Ameliorating treatment-refractory depression with intranasal ketamine: potential NMDA receptor actions in the pain circuitry representing mental anguish.

Opler LA, Opler MG, Arnsten AF.

CNS Spectr. 2016 Feb;21(1):12-22. doi: 10.1017/S1092852914000686. Epub 2015 Jan 26. Review.

18.

Synaptic dysfunction in depression: potential therapeutic targets.

Duman RS, Aghajanian GK.

Science. 2012 Oct 5;338(6103):68-72. doi: 10.1126/science.1222939. Review.

19.

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.

Gerhard DM, Wohleb ES, Duman RS.

Drug Discov Today. 2016 Mar;21(3):454-64. doi: 10.1016/j.drudis.2016.01.016. Epub 2016 Feb 6. Review.

20.

The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine.

Monteggia LM, Gideons E, Kavalali ET.

Biol Psychiatry. 2013 Jun 15;73(12):1199-203. doi: 10.1016/j.biopsych.2012.09.006. Epub 2012 Oct 11. Review.

Supplemental Content

Support Center